help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mascardo, R. N.
Right arrow Articles by Sherline, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mascardo, R. N.
Right arrow Articles by Sherline, P.

Endocrinology, Vol 111, 1394-1396, Copyright © 1982 by Endocrine Society

ARTICLES

Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor

RN Mascardo and P Sherline

The role of endogenous growth inhibitors in the regulation of cell proliferation is unclear. Although there are numerous studies on the stimulatory effect of peptide hormones such as insulin, the somatomedins and epidermal growth factor (EGF) on cell proliferation, little is known about the existence of hormones that might exert an antiproliferative effect on cells. Somatostatin (SS), a cyclic tetradecapeptide hormone that is widely distributed in the body, exerts an inhibitory effect on numerous cellular processes. We observed that SS at concentrations of 10(-8) - 10(13M), inhibited EGF-induced centrosomal separation, which recent evidence suggests is necessary for DNA synthesis in response to EGF. This SS effect was associated with inhibition of DNA synthesis and cell replication induced by EGF in gerbil fibroma and HeLa cells. Inhibition of centrosomal separation and the consequent antiproliferative effect of SS may represent a biologically significant action of this ubiquitous hormone.


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. Canzian, J. D. McKay, R. J. Cleveland, L. Dossus, C. Biessy, C. Boillot, S. Rinaldi, M. Llewellyn, V. Chajes, F. Clavel-Chapelon, et al.
Genetic Variation in the Growth Hormone Synthesis Pathway in Relation to Circulating Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Breast Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Study
Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2316 - 2325.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. J. Fueger, G. Hamilton, M. Raderer, T. Pangerl, T. Traub, P. Angelberger, G. Baumgartner, R. Dudczak, and I. Virgolini
Effects of Chemotherapeutic Agents on Expression of Somatostatin Receptors in Pancreatic Tumor Cells
J. Nucl. Med., December 1, 2001; 42(12): 1856 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. T. Dolan, D. M. Miltenburg, T. S. Granchi, C. C. Miller, and F. C. Brunicardi
Treatment of Metastatic Breast Cancer With Somatostatin Analogues--A Meta-Analysis
Ann. Surg. Oncol., April 1, 2001; 8(3): 227 - 233.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Wangberg, O. Nilsson, V. Johanson, L. Kolby, E. Forssell-Aronsson, P. Andersson, M. Fjalling, L.-E. Tisell, and H. Ahlman
Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumors
Oncologist, February 1, 1997; 2(1): 50 - 58.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society